OR WAIT null SECS
Jonathan Alicea is an assistant editor for HCPLive. He graduated from Princeton University with a degree with English and minors in Linguistics and Theater. He spends his free time writing plays, playing PlayStation, enjoying the company of his 2 pugs, and navigating a right-handed world as a lefty. You can email him at firstname.lastname@example.org.
Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.
On the morning of Day 1 of the American Academy of Dermatology (AAD) Virtual Meeting Experience, dual studies were published in The New England Journal of Medicine showing the superiority of IL-17A/IL-17F inhibitor bimekizumab over IL-7A inhibitor secukinumab and TNFα inactivator adalimumab for the treatment of plaque psoriasis.
Both studies—dubbed the BE RADIANT and BE SURE trials, respectively—are just 2 of many that make up the bimekizumab clinical trial program.
Similarly, data published this past February in The Lancet showed the biologic betters the IL-12/IL-23 inhibitor ustekinumab in the primary endpoint of skin clearance (as measured by the Psoriasis Area and Severity Index). These results were from the BE VIVID and BE READY clinical trials.
Jeffrey Stark, MD, Head of Immunology Medical Affairs at UCB, talked to HCPLive® about the value of the clinical trial program, highlighting the most noteworthy data from its studies. He offered perspective on the BE VIVID and BE READY trials, discussing the implications the data has in terms of bimekizumab’s potential for patients with plaque psoriasis.
He also highlighted the recent BE RADIANT findings, suggesting it as especially revelatory for bimekizumab.
It is “the first Phase 3 head-to-head study to compare the efficacy and safety of dual IL-17A and IL-17F inhibition with the inhibition of IL-17A alone,” Stark explained. “We’re very happy to be able to share this data for the first time.”
The late-breaking study was presented alongside 11 other posters showing various components of the drug’s safety and efficacy in this patient population.